GLP-1, Weight Loss and Rosie O'Donnell
Digest more
Glucagon-like peptide-1 (GLP-1) receptor agonist use is booming in the U.S., and it’s ushering in waves of reports of people drinking less or craving less alcohol after they’ve been prescribed a GLP-1 for weight loss or type 2 diabetes.
Since 2024, GLP-1 use has quadrupled, with usage at an all-time high in the U.S. A new study highlights women GLP-1 users, and how they are perceived in the workplace.
Wegovy, Ozempic and Zepbound have positives beyond weight loss – and Medicare’s change could accelerate the benefits.
I travel often for work, but starting Wegovy changed the way I plan and experience trips. I wish I'd known more about traveling on a GLP-1.
1don MSN
Scientists thought GLP-1s would improve happiness and relationships. The data told a different story
A new working paper examined whether GLP-1 drugs had an effect on the social or mental wellbeing of people with diabetes. The findings were surprising.
Withings, a pioneer in clinical-grade connected health devices, today announced the publication of a peer-reviewed study in Mayo Clinic Proceedings: Digital Health providing a real-world analysis of how body composition changes in individuals using GLP-1 receptor agonist therapy.
People with obesity in the United States are being sorted between haves and have-nots. Primary care doctor Ian Huntington has been counseling low-income Boston patients how to keep their weight under control, after the state’s Medicaid program stopped covering GLP-1 drugs for weight loss this month.
A new study reveals that dropping coverage for weight-loss drugs like Ozempic could backfire—costing companies up to $866 per worker in lost productivity.
Fast food chains are responding to the GLP-1 boom with high-protein menus and smaller portions, some priced lower than traditional meals.
A study of workers in Denmark showed a 17.3 percent decline in long-term sick leave among those who were treated with Ozempic, the diabetes drug, according to results published this month in a National Bureau of Economic Research working paper.
Despite the president’s comments, patients say these medications have been life-changing, and their effectiveness cannot be ignored.